Webcasts for Healthcare Professionals

Choose from a selection of presentations by Canadian Healthcare Professionals and other guest speakers, including:
  • Practical Keys to Successful CGM: With Special Guest Speaker: Margaret Lawson, MD, MSc, FRCP.  & Christine Richardson, RN., BScN., CDE
  • Type 1 Diabetes and Exercise: Optimizing the Medtronic MiniMed® VeoTM Insulin Pump and Continuous Glucose Monitoring for Better Glucose Control1,2With Special Guest Speakers:  Dr. Bruce Perkins, MD MPH & Dr. Michael Riddell, PhD
  • Interpreting Medtronic Continuous Glucose Monitoring and Medtronic CareLink® Data to Advance Diabetes Patient Care: With Special Guest Speakers:  Dr. Bruce Perkins, MD MPH & Professor Ohad Cohen, MD 
  • Medtronic CGM Technology, Enhanced Enlite®, Real Life Data and Beyond: With Special Guest Speaker:  Cary Talbot, BSE Engineering
  • Clinical Trials for CGM and Enhanced Enlite™: New Developments Regarding the Artificial Pancreas and Results from the OpT2mise Study: With Special Guest Speakers: Dr. Rémi Rabasa-Lhoret, MD, PhD, Dr. S. John Weisnagel, MD, Dr. Jean-François Yale, MD, CSPQ, FRCPC, Séverine Liabat, MSc Biomedical Engineering, Director of Clinical Research and Medical Programs at Medtronic International

MiniMed® QuickStart 

Web-based software designed to set up your patient’s pump settings on the Veo™ pump. Click here to access the MiniMed® QuickStart site: www.medtronicdiabetes.ca/quickstart

myLearning online Medtronic product training modules

Designed for patients and Healthcare Professionals. Topics include: pump set-up, continuous glucose monitoring, infusion site management and more. Access myLearning.

MiniMed® Veo™ with Low Glucose Suspend

The MiniMed® Veo™ is the only sensor-augmented pump with a low glucose suspend feature- which is clinically proven to significantly reduce hypoglycemia events1. 
LGS has been proven to1:
  • 37.5% less nocturnal hypoglycemia exposure
  • 29.8% reduction in the number of hypo events during the night and day
  • Decreased hypo exposure without deteriorating HbA1C or significant rebound hyperglycemia 

Insulin Pumps & Type 2 Diabetes: The OpT2mise Study

Significant HbA1c reduction for type 2 diabetes, now clinically proven, with the MiniMed® Veo™ insulin pump2
The Medtronic-sponsored OpT2mise study is the largest (331 patients) randomized, controlled trial on insulin pump technology for type 2 diabetes. This international, multicenter (36 centers around the globe), parallel-group study consisted of a run-in period, a six-month randomized phase and a six-month continuation phase. CSII use in sub-optimally controlled T2D provides improvements in overall glucose control vs MDI2:
  • Significant decrease in HbA1C levels (-1.1% vs baseline,  -0.7% between group difference)
  • 55% of patients achieving HbA1C < 8%
  • Significant reduction in the time spent in hyperglycemia
  • No increase in the time spent in hypoglycemia
  • 20% less insulin used


  • 1 Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311-320
  • 2 Reznik Y. Cohen O. Aronson R. et al, Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet 2014 Jul 2. pii: S0140-6736(14)61037-0. doi: 10.1016/S0140-6736(14)61037-0